Imatinib mesylate, which is a competitive inhibitor of certain tyrosine kinases including intracellular kinases ABL and the BCR-ABL fusion proteins present in some leukemias, and PDGFRA, is the first effective drug for GIST [[16,17], 18]. This evidence concerns the gene BCR and leukemia.